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Abstract
Microarray studies of chronic hepatitis C infection have provided valuable information regarding the host response to viral
infection. However, recent studies of the human transcriptome indicate pervasive transcription in previously unannotated
regions of the genome and that many RNA transcripts have short or lack 39 poly(A) ends. We hypothesized that using
ENCODE tiling arrays (1% of the genome) in combination with affinity purifying Pol II RNAs by their unique 59 m
7GpppN cap
would identify previously undescribed annotated and unannotated genes that are differentially expressed in liver during
hepatitis C virus (HCV) infection. Both 59-capped and poly(A)+ populations of RNA were analyzed using ENCODE tiling
arrays. Sixty-four annotated genes were significantly increased in HCV cirrhotic as compared to control liver; twenty-seven
(42%) of these genes were identified only by analyzing 59 capped RNA. Thirty-one annotated genes were significantly
decreased; sixteen (50%) of these were identified only by analyzing 59 capped RNA. Bioinformatic analysis showed that
capped RNA produced more consistent results, provided a more extensive expression profile of intronic regions and
identified upregulated Pol II transcriptionally active regions in unannotated areas of the genome in HCV cirrhotic liver. Two
of these regions were verified by PCR and RACE analysis. qPCR analysis of liver biopsy specimens demonstrated that these
unannotated transcripts, as well as IRF1, TRIM22 and MET, were also upregulated in hepatitis C with mild inflammation and
no fibrosis. The analysis of 59 capped RNA in combination with ENCODE tiling arrays provides additional gene expression
information and identifies novel upregulated Pol II transcripts not previously described in HCV infected liver. This approach,
particularly when combined with new RNA sequencing technologies, should also be useful in further defining Pol II
transcripts differentially regulated in specific disease states and in studying RNAs regulated by changes in pre-mRNA
splicing or 39 polyadenylation status.
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Introduction
Microarray based gene analyses have provided a new approach
to identifying disease-specific changes in gene expression. This
approach has improved the understanding of molecular pathobi-
ology by identifying genes that are differentially regulated in
selected diseases and by identifying biomarkers for disease states or
responses to therapy. Successful examples of this approach include
identifying subtypes of diffuse large B-cell lymphomas with
different prognoses and increased expression of the zeta-chain
(TCR) associated 70 kDa protein kinase (ZAP70) in chronic
lymphocytic leukemia (CLL) which is a predictor of the clinical
course [1,2,3]. Examples in stratifying breast cancer include
identifying a panel of transcriptional changes predicting distant
metastasis in lymph-node-negative patients, predicting the re-
sponse to specific therapies and survival of patients [4,5,6,7,8,9].
Progress towards stratifying patients with colon cancer using gene
expression signatures was recently reported [10].
In hepatitis C infection, gene array analyses in chimpanzees
identified host responsive gene pathways in acute and chronic
hepatitis C infection [11]. Gene array studies have also been used
to identify potential biomarkers of hepatitis C infection, interferon
regulated genes which predict the response to therapy, and gene
expression patterns which predict early progression to fibrosis in
liver transplant recipients [12,13,14]. Unique gene expression
profiles were also identified which distinguish alcoholic liver
disease and hepatitis C as well as hepatitis B and hepatitis C
infection [15,16]. More recent data suggests that the hepatitis C
virus may regulate host non-coding RNAs (i.e., miRNAs) to
promote viral replication [17].
One limit of standard oligonucleotide or cDNA microarrays is
that they require prior knowledge of the sequence of the RNA that
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e14697will be measured. In addition, many arrays are purposefully biased
to interrogate sequences originating from 39 ends of mRNA
encoded by the 39 terminal exon of previously annotated genes.
Although these methods measure RNA transcripts from well-
annotated protein coding genes and selected ncRNAs, they do not
generally provide information regarding pre-mRNAs and most
non-coding RNAs that can be important in physiological or
pathological processes. Genomic tiling arrays or next generation
sequencing provide a useful alternative for quantifying and
characterizing transcription across the genome without requiring
prior knowledge of gene or RNA transcript sequences. Tiling
arrays are designed to cover the entire genome, selected
chromosomes or contigs of the genome. Recent gene expression
experiments using ENCODE (Encyclopedia of DNA Elements)
tiling arrays, representing 1% of the human genome, have
demonstrated that much of the genome is transcribed and that
most nucleotides appear to be present in at least some form of
RNA transcript [18]. A recent study in Schizosaccharomyces pombe
provides further evidence for extensive sense and antisense
transcription [19]. The nature of these RNAs, the RNA
polymerase responsible for their transcription and their biological
function remain unknown.
Previous ENCODE studies analyzed polyadenylated [poly(A)+]
RNA, but recent data suggests that many RNAs in yeast and
mammals either lack or have short 39 poly(A) ends and are
underrepresented or absent in microarray analyses using poly(A)+
RNA [18,20]. To enhance the selection of Pol II transcripts we
have developed an efficient method of purifying RNA polymerase
II (Pol II) transcripts regardless of their 39 polyadenylation status.
Pol II RNAs have a 59 m7GpppN cap added enzymatically to
their 59 ends during the pausing phase of transcription [21,22].
Our approach purifies Pol II transcripts by binding their 59 caps
with a high-affinity variant of the RNA cap binding protein
(eIF4EK119A) [20,23]. When compared to standard poly(A)+
dependent purifications the yield of 59 capped RNA is 2–3 fold
greater from the same quantity of total RNA starting material,
suggesting that poly(A)+ purification does not recover all capped
Pol II RNAs [20].
To date, no gene expression studies on hepatitis C infected liver
have been performed using tiling array analyses such as
ENCODE. The goal of this study was to identify differentially
expressed annotated genes and novel RNAs in hepatitis C infected
liver that would not typically be recorded by analyzing poly(A)+
RNA with standard gene expression arrays. In this study, we
utilized 59 capped and poly(A)+ RNA populations isolated from
control and chronically infected hepatitis C (HCV) cirrhotic
human liver biospecimens using ENCODE tiling arrays to
measure differential expression of Pol II RNAs. Differentially
expressed RNAs identified in this analysis were then measured by
real-time PCR (qPCR) in additional control, mild chronic hepatitis
C (no fibrosis) and chronically infected hepatitis C cirrhotic
biospecimens.
Results
The ENCODE tiling array analysis of 59 capped RNA
identified 47 annotated genes with increased expression (fold
change .1.5, Bonferroni adjusted p value ,0.05) (Figure 1A) and
22 genes with decreased expression in a chronic hepatitis C (HCV)
cirrhotic as compared to an uninfected control liver specimen
(Figure 1B). Analysis of poly(A)+ RNA identified 37 genes with
increased expression and 15 genes with decreased expression in
HCV cirrhotic as compared to control liver. Twenty of the
upregulated genes and six of the downregulated genes were
identified in both 59 capped and poly(A)+ RNA populations
(Figure 1). Of note, 8 out of 17 upregulated genes (47%) and 2 out
of 9 down-regulated genes (22%) unique to poly(A)+ RNA did
have a statistically significant expression difference (p,0.05) in 59
capped RNA, but were excluded from our list because their fold
change did not meet the inclusion criteria (,1.5). None of 27
upregulated or 17 downregulated genes unique to 59 capped RNA
were found to have significant differential expression in the
poly(A)+ RNA (see Tables S1, S2, S3, S4, S5, S6). This is likely
due to less variation in signal intensity observed with 59 capped
RNA among experimental replicates as compared to poly(A)+
RNA (the average SEM per gene was 28.1 for 59 capped; poly(A)+
average SEM per gene was 77.2).
Thirteen of the 64 genes (20%) found to be upregulated in HCV
cirrhotic liver were identified by GO-term enrichment analysis to
have biologic functions related to the immune response (Table 1)
[24,25]. Several of these genes were selected for qPCR analysis of
liver tissue from multiple patients, including interferon regulatory
factor 1 (IRF1), a transcription factor involved in the interferon
response to HCV infection in-vitro [26]. On ENCODE analysis,
IRF1 was found to be upregulated in HCV cirrhotic liver in 59
capped RNA only (fold change 2.1, p=0.03, Figure 2A). qPCR
analysis of IRF1 in multiple patient samples confirmed the
ENCODE findings of increased expression in HCV cirrhotic liver
(n=7) compared to control liver (n=10) (fold change 2.4, p=0.03,
Figure 2B). Percutaneous liver biopsies (n=7) from patients with
chronic hepatitis C with mild inflammation and no fibrosis (Metavir
grade 1, stage 0) were also analyzed and showed a significant
increase in IRF1 expression (fold change 3.5, p=0.001, Figure 2B).
These patients were not being treated with recombinant interferon
at the time of liver biospecimen acquisition.
The tripartite motif-containing 22 (TRIM22) mRNA, encoded
by an interferon regulated gene previously reported to be
upregulated with HIV and hepatitis B viral infections [27,28],
was also found to have increased expression in our analysis of
HCV cirrhotic liver. TRIM22 was increased on ENCODE
analysis in both 59 capped (fold change 4.1, p,0.001) and
poly(A)+ RNA (fold change 6.2, p=0.001, Figure 3A); we also
identified increased transcription in intronic regions within the
TRIM22 gene. qPCR analysis of TRIM22 showed a large
increased expression (fold change 9.7, p,0.001) in HCV cirrhotic
liver (Figure 3B). Liver biopsies from patients with mild chronic
hepatitis C and no fibrosis showed a marked increase in TRIM22
expression (fold change 17.0, p,0.001, Figure 3B).
Connective tissue growth factor (CTGF) mRNA is upregulated
during liver fibrosis and its protein product has recently been
suggested as a non-invasive biomarker of liver fibrosis in patients
infected with hepatitis C [29]. CTGF mRNA was upregulated in
both 59 capped (fold change 5.5, p,0.001) and poly(A)+ RNA
(fold change 13, p,0.001, Figure S1A). qPCR analysis of liver
tissue from multiple control and HCV cirrhotic liver specimens
showed a large mean increase in CTGF expression (fold change 17,
p=0.004) (Figure S1B). Interestingly, qPCR analysis of liver
biopsies with mild chronic hepatitis C with no fibrosis showed no
increase in CTGF expression (fold change 25.7, p=0.03, Figure
S1B).
Several other differentially expressed genes identified in the
ENCODE tiling array analysis were selected for qPCR analysis
using additional patient samples. The Met proto-oncogene (MET)
is the hepatocyte growth factor receptor and has been implicated
in the development of multiple tumor types. ENCODE array
analysis of 59 capped RNA showed decreased expression of MET
in hepatitis C cirrhotic liver (fold change 21.8, p=0.015, Figure
S2A). However, qPCR analysis of multiple patients did not
ENCODE Analysis of 59 Cap RNA
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cirrhotic liver (Figure S2B). However, qPCR analysis of mild
chronic hepatitis C biopsies with no fibrosis showed a significant
increase in MET expression (fold change 3.7, p=0.002, Figure
S2B).
Cathepsin D (CTSD), a lysosomal aspartyl protease associated
with several disease processes, was significantly upregulated in the
ENCODE array analysis of 59 capped RNA from hepatitis C
cirrhotic liver (fold increase 1.9, p,0.001). However, when
multiple patient samples were analyzed by qPCR no significant
difference was identified (data not shown). The FUN14 domain
containing 2 (FUNDC2) mRNA, encoding a protein suggested to
interact with hepatitis C core protein, was downregulated in 59
capped RNA from hepatitis C cirrhotic liver (fold change 22.1,
p,0.001) [30]. However, when specimens of liver from additional
patients with hepatitis C cirrhosis were analyzed by RT-PCR no
significant difference was seen (data not shown). Nevertheless, RT-
PCR of cDNA prepared from the same liver specimens (HCV
cirrhotic 1 and Control 1) used in the ENCODE tiling array
analysis did verify that MET, CTSD and FUNDC2 were both
significantly different in those specimens (data shown for MET
only).
Differential gene expression associated with HCV cirrhotic liver
was also observed in non-protein coding genomic regions
including intronic and intergenic regions. Figure 4 illustrates the
differential gene expression observed in exonic, intronic, and
intergenic regions in 59 capped and poly(A)+ RNA. Fifty percent
of the upregulated and 78% of the downregulated nucleotides
were found in intronic regions using 59 capped RNA, as compared
to 23% of the upregulated and 49% of the reduced nucleotides
when poly(A)+ RNA was analyzed. A similar percentage of
differentially expressed nucleotides were observed in intergenic
regions when 59 capped (4–10%) and poly(A)+ (8–10%) RNA
samples were analyzed. Four annotated genes provide examples of
higher intronic expression in 59 capped as compared to poly(A)+
RNA: hepatocyte growth factor receptor (MET); tissue inhibitor of
metalloproteinase 3 (TIMP3); mitogen-activated kinase kinase
kinase 1 (MAP3K1); MyoD family inhibitor domain containing
(MDFIC); and (Figures S2 and S3).
Our ENCODE tiling array analysis of both 59 capped and
poly(A)+ RNA identified three differentially expressed transcrip-
tionally active genomic regions where no annotated genes exist.
These 59 capped RNA transcript regions originated from
chromosome 14 (Figure 5A, coordinates 53,254,000–53,256,899),
chromosome 9 (Figure 6A, coordinates 131,088,154–131,089,262)
and chromosome 21 (Figure S4A, coordinates 39,253,256–
39,413,500). All three of these genomic regions demonstrated
RNA transcription at least 10 kb from annotated genes. Although
these regions were found to be transcribed in previous ENCODE
tilingarray analysis of HL60, HeLa, and Gm06990 human cell lines
(Figure S5, http://genome.ucsc.edu/ENCODE/pilot.html), there
was no prior evidence that they represented 59 capped Pol II RNAs.
Further investigation using the UCSC genome browser (http://
genome.ucsc.edu) identified several ESTs (spliced and unspliced)
originating from the transcribed region identified on chromosome 9
(Figure S6A). Notsurprisingly, the 160kb region on chromosome21
included several ESTs (BE870595, BG459638, BG460250,
BI011795) and overlapped with one hypothetical protein
(AJ011409, unpublished). It also included previously identified 59
Rapid Amplification of cDNA Ends (RACE) products [31]. The 59
capped RNA transcript(s) originating from the unannotated region
of chromosome 14 did not overlap with any known genes in the
UCSC database but was associated with a SNP (rs2884435) and
several unspliced ESTs (Figure S6B).
qPCR analysis of the 59 capped Pol II RNA(s) originating from
the unannotated region on chromosome 14 confirmed the
presence of a RNA transcript that was increased 7.8 fold in seven
HCV cirrhotic as compared to ten control liver specimens
(p,0.001) (Figure 5B). Moreover, qPCR analysis of mild chronic
hepatitis C biopsies with no fibrosis showed a similar increase in
expression of the transcript (fold change 11.3, p=0.003,
Figure 5B).
The 59 capped RNA originating from the unannotated region on
chromosome 9 was also confirmed to have a 4.5 fold increase by
Figure 1. Differentially expressed genes in HCV cirrhotic versus control liver when analyzing 59 or 39 isolated RNA. Panel A. The
number of genes with RNA levels that were increased in hepatitis C (HCV) cirrhotic as compared to control liver in the 59 capped, poly(A)+, and both
RNA populations are shown. Panel B. The number of genes with RNA levels that were decreased in HCV cirrhotic as compared to control liver in 59
capped, poly(A)+, or both RNA populations are shown. RNA transcripts were isolated from HCV cirrhotic and control liver with the 59 cap and poly(A)+
dependent purifications described in Methods. Four experimental replicates of HCV cirrhotic and control liver were used for this analysis. cDNA was
synthesized using random hexamers and used to prepare probes (Methods). RNA transcript expression was measured by averaging fluorescent signal
intensity on Agilent ENCODE gene arrays for each sample. Annotated genes with $1.5 fold changes and Bonferroni corrected p values ,0.05 in HCV
cirrhotic as compared to control liver were included in this figure.
doi:10.1371/journal.pone.0014697.g001
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liver specimens (p,0.001) (Figure 6B). qPCR analysis of mild
chronic hepatitis C with no fibrosis showed a similar increase in
expression of the transcript (fold change 4.1, p=0.002, Figure 6B).
Table 1. Differentially Expressed Genes Associated with Immune Response.
Gene Name
(Ensembl) Description
Isolation
Technique
Mean Signal
Intensity HCV
Liver
Mean Signal
Intensity
Control Liver
Fold
Change
Bonferroni p
Value
Upregulated only in 59 capped RNA
*IRF1 Interferon regulatory factor 1 (IRF-1) 59 Capped RNA 674 323 2.09 0.033
Poly(A)+ RNA 2087 1363 1.53 51.505
LILRA1 Leukocyte immunoglobulin-like receptor subfamily A
member 1 Precursor
59 Capped RNA 192 121 1.58 ,0.001
Poly(A)+ RNA 219 171 1.28 18.386
LILRA4 Leukocyte immunoglobulin-like receptor subfamily A
member 4 Precursor
59 Capped RNA 106 64 1.64 ,0.001
Poly(A)+ RNA 126 102 1.24 7.956
*LILRB2 Leukocyte immunoglobulin-like receptor subfamily B
member 2 Precursor
59 Capped RNA 756 359 2.1 0.015
Poly(A)+ RNA 1186 756 1.57 7.591
*LILRB4 Leukocyte immunoglobulin-like receptor subfamily B
member 4 Precursor
59 Capped RNA 191 92 2.06 ,0.001
Poly(A)+ RNA 378 246 1.54 0.388
RFX5 DNA-binding protein RFX5 59 Capped RNA 292 174 1.68 ,0.001
Poly(A)+ RNA 899 523 1.72 0.729
TRIM34 Tripartite motif-containing protein 34 59 Capped RNA 108 65 1.67 ,0.001
Poly(A)+ RNA 204 138 1.48 0.76
Upregulated only in Poly(A)+ RNA
LEAP2 Liver-expressed antimicrobial peptide 2 Precursor 59 Capped RNA 139 98 1.42 0.003
Poly(A)+ RNA 626 712 2.96 0.001
LILRA5 Leukocyte immunoglobulin-like receptor subfamily A
member 5 Precursor
59 Capped RNA 65 63 1.04 221.422
Poly(A)+ RNA 425 217 1.95 0.013
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 59 Capped RNA 121 94 1.29 0.037
Poly(A)+ RNA 482 226 2.13 0.021
PSMB4 Proteasome subunit beta type-4 Precursor 59 Capped RNA 390 393 21.01 501.381
Poly(A)+ RNA 14358 4689 3.06 0.013
Upregulated in both 59 capped and Poly(A)+ RNA
*TRIM22 Tripartite motif-containing protein 22 59 Capped RNA 824 201 4.11 ,0.001
Poly(A)+ RNA 3390 545 6.22 0.001
LAIR1 Leukocyte-associated immunoglobulin-like receptor 1
Precursor
59 Capped RNA 199 85 2.34 ,0.001
Poly(A)+ RNA 337 148 2.28 0.001
Downregulated only in 59 capped RNA
IFNAR1 Interferon-alpha/beta receptor alpha chain Precursor 59 Capped RNA 312 646 22.07 0.013
Poly(A)+ RNA 741 1220 21.65 1.132
LILRB3 Leukocyte immunoglobulin-like receptor subfamily B
member 3 Precursor
59 Capped RNA 83 138 21.66 ,0.001
Poly(A)+ RNA 922 980 21.06 401.425
Pol II RNA transcripts were isolated from HCV cirrhotic and control liver via two methods. 59 capped RNA was isolated using a high affinity variant eIF4E protein, poly(A)+
RNA was isolated with oligo-dT (Qiagen) and cDNA was synthesized with random primers (Methods). RNA transcript expression was measured by averaging fluorescent
signal intensity on Agilent’s ENCODE gene arrays for each sample (Methods). Differences in gene expression were visualized using Genoviz’s Integrated Genome
Browser software. Only annotated genes with $1.5 fold and Bonferroni corrected p values ,0.05 between HCV cirrhotic and control liver are listed with details of their
expression. Genes are listed by the specific pool of RNA analyzed. No genes with decreased expression in HCV cirrhotic liver were found in the poly(A)+ RNA. Genes
which have been previously documented to have increased expression in HCV cirrhotic liver are marked with *. Only genes associated with the immune response are
listed above. A complete list of differentially expressed genes is provided in supplemental materials.
doi:10.1371/journal.pone.0014697.t001
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among multiple patients with HCV cirrhosis using qPCR.
To further define the structure of differentially expressed
RNA(s) originating from chromosome 9 and 14, we used 59 and
39 rapid amplification of cDNA ends (RACE) and DNA
sequencing over one region on chromosome 9 and three separate
regions of chromosome 14 (Chr14a, Chr14b, and Chr14c) where
differential expression was observed by ENCODE analysis. Using
5’ RACE we identified the 59 end of an unannotated RNA
transcript found on chromosome 9 (Figure S6A). The 59 end of
this transcript was at a similar chromosome coordinate as other
previously identified ESTs. Using 39 RACE we identified the 39
ends of independent RNA transcripts on the minus strand of
Chr14a and Chr14b regions, respectively (Figure S6B). We also
sequenced approximately 600–800 nucleotides including the
poly(A)+ end of each transcript. The existence of at least a
1.50 kb transcript in the chromosome 14c region was confirmed
by standard PCR product sequencing. To compare relative
expression of RNA transcripts on the Chr14a and Chr14c regions
we performed qPCR analysis. Interestingly, gene expression was
similar in the HCV cirrhotic and control human liver samples but
more than 10-fold higher in the Chr14a region compared to the
Chr14c region in Huh7.5 cells, a human hepatoma cell line (data
not shown).
Figure 2. Differential expression of IRF1 in HCV cirrhotic as compared to control liver. Panel A. Expression of IRF1 as measured by signal
intensity on ENCODE tiling arrays is displayed using the Integrated Genome Browser (IGB). The y-axis represents the log2 transformation of the
normalized signal divided by the background signal on arrays and each bar represents the normalized signal intensity of probes hybridized to 60mer
targets tiled across the gene region (Methods). Genomic regions that are tiled yet lack a signal are indicated by a baseline tick mark. Absence of a tick
mark indicates no probes in that region. Gene structure, orientation, and chromosomal location are shown in black. Average RNA expression based
on the analysis of 59 capped RNA isolated from HCV cirrhotic and control liver is depicted in green for both HCV cirrhotic and control liver. Average
RNA expression using poly(A)+ RNA is depicted in blue. Differences in expression between HCV cirrhotic and control liver for poly(A)+ and 59 capped
RNA populations are depicted as window level false discovery rates in red (-10Log10 FDR) (see Methods). A transformed FDR of $13 (represents an
untransformed FDR #0.05 or 5 false positives out of 100) was considered statistically significant. Panel B. qPCR was performed as described in
Methods. Triplicate samples from seven HCV cirrhotic, seven mild HCV (no fibrosis), and ten control livers were analyzed. HCV Cirrhotic 1 and Control
1 refer to the original samples used for the ENCODE tiling array analysis. The mean 6 SEM fold change for each specimen analyzed is shown and the
location of the qPCR primers is indicated by qPCR in Panel A. P-values were calculated using the Student’s t-test.
doi:10.1371/journal.pone.0014697.g002
ENCODE Analysis of 59 Cap RNA
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The quantitative analysis of RNA transcripts in control and
diseased tissue to define differential gene expression and aid
biomarker discovery has generally used cDNA derived from total
or poly(A)+ RNA hybridized to oligonucleotide microarrays.
Recent studies of RNA transcription in human cells using
ENCODE tiling arrays and poly(A)+ RNA have surprisingly
described extensive transcription in previously unannotated
genomic regions [18,31,32]. A consistent observation in these
studies has been unexpectedly high transcription in unannotated
and intronic regions of the genome. For example, a high-
resolution strand-specific analysis of the entire transcriptome of
S. pombe showed extensive transcription including intergenic and
antisense transcription [19]. In addition, studies suggest that the
number of Pol II transcripts with absent or short poly(A)+ ends
may be markedly underestimated (ref 18, 20). Based on these
findings it seems likely that standard microarray analyses are
underestimating disease specific gene expression changes. In this
study we tested this possibility by analyzing gene expression
changes in hepatitis C (HCV) cirrhotic as compared to control
liver in both 59 capped and poly(A)+ populations of RNA using
ENCODE tiling arrays representing 1% of the genome.
Differential gene expression between HCV cirrhotic and control
liver, in most cases, was observed with a greater sensitivity and
additional detail when 59 capped RNA was analyzed as compared
to poly(A)+ RNA (Table 1). Although many of the differentially
expressed transcripts identified using poly(A)+ RNA had higher
fold changes, the variability between experimental replicates was
greater resulting in failed statistical testing. One possible
explanation for the increased consistency in analyzing 59 capped
as compared to poly(A)+ RNA could be variability of the poly(A)+
ends. Short poly(A)+ ends have been demonstrated for a number
of well-annotated genes in human liver, such as eNOS mRNA in
vascular endothelial cells, and is a well-documented mechanism
for regulating gene expression in developmental models
[20,33,34]. Moreover, examples of mRNAs with a poly(A)-limiting
element in their 39 end, such as the Xenopus albumin mRNA
Figure 3. Differential expression of TRIM22 in HCV cirrhotic as compared to control liver tissue. Panel A. The expression of TRIM22 as
measured by signal intensity on ENCODE tiling arrays are displayed using the IGB. The data are displayed as in Figure 2. Panel B. qPCR was
performed as described for Figure 2 and in Methods.
doi:10.1371/journal.pone.0014697.g003
ENCODE Analysis of 59 Cap RNA
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e14697produced by liver, have poly(A)+ ends of ,20 nts yet are efficiently
translated [35].
Additional differences observed in the ENCODE tiling array
analysis of 59 capped and poly(A)+ RNA populations included
differences in signal intensity across specific regions of each gene
transcript. In most cases the signal intensities at the 39 end of
transcripts were greater when poly(A)+ RNA was analyzed as
compared to 59 capped RNA. In some cases the signal on tiling
arrays was greater in the 59 end of annotated genes when 59
capped RNA was analyzed as compared to poly(A)+ RNA. With
some gene transcripts, such as the hepatocyte growth factor
receptor (MET), tissue inhibitor of metalloproteinase 3 (TIMP3),
MyoD family inhibitor domain containing (MDFIC) and mitogen-
activated kinase kinase kinase 1 (MAP3K1), higher levels of
transcription was observed in intronic regions when 59 capped
RNA was analyzed as compared to poly(A)+ RNA. This is
consistent with the 59 capped RNA purification that includes
unspliced heterogeneous nuclear RNA (hnRNA) as well as mature
spliced RNA, while the poly(A) dependent purification predom-
inantly represents mature spliced RNA.
We identified many immune response genes that were
significantly increased in HCV cirrhotic as compared to control
liver, as other studies have, and found upregulated genes that were
not identified previously by gene array analysis. These included
IRF1, tripartite motif-containing 22 (TRIM22), and multiple
leukocyte immunoglobulin-like receptors (LILRA1, LILRA4,
LILRA5, LILRB2, LILRB3 and LILRB4) [14,16,36]. IRF1
transcription was significantly increased in HCV cirrhotic as
Figure 4. Differential gene expression observed in exonic, intronic, and intergenic regions in 59 capped and poly(A)+ RNA. Pie charts
depict the relative percentage of differentially expressed nucleotides in HCV cirrhotic liver as compared to control liver using 59 capped RNA (Panel
A) or poly(A)+ RNA analysis (Panel B). Charts on the left show increased expression and charts on the right show reduced expression. The
percentage of differentially expressed nucleotides found in intronic, exonic, and intergenic regions are shown for 59 capped and poly(A)+ RNA
samples.
doi:10.1371/journal.pone.0014697.g004
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not when poly(A)+ RNA was analyzed. IRF1 is a critical
transcriptional regulatory factor that modulates interferon stimu-
lated gene (ISG) expression and has been shown to regulate HCV
subgenomic replicon activity in cultured hepatoma cells [37,38].
Interestingly, polymorphisms in the IRF1 promoter have been
reported to be associated with a better response to interferon alpha
(IFN-a) therapy in patients with chronic hepatitis C [39].
Tripartite motif (TRIM) 22 was another immune response related
gene that was significantly increased in HCV cirrhotic as
compared to control liver in our analysis. The tripartite motif
family of proteins has been associated with innate immunity to
viruses by restricting viral replication [40]. TRIM22 is dramatically
upregulated by interferon signaling and decreases HIV replication
(Barr et al., 2008). In addition, it has recently been shown to
suppress HBV replication in culture [28]. Genome wide
expression array analysis of both chimpanzee and human liver
tissue have provided evidence for increased expression of TRIM22
in hepatitis C infected liver, however this is the first report to
confirm its increased expression in HCV infected human liver
(both cirrhotic and non-fibrotic) using real time PCR [11,12,41].
The qPCR analysis of biopsies showing mild hepatitis C without
fibrosis provide evidence that the upregulation of IRF1, TRIM22,
and MET are authentically due to HCV infection, and not due to
major changes in liver tissue cell type.
Further evidence of alterations in immune response function
includes the upregulation of multiple leukocyte immunoglobulin-
like receptors. These receptors, also known as immunoglobulin-
like transcripts (ILTs), are expressed on myelomonocytic cells and
can influence both the innate and acquired immune response [42].
LILRB2, the most highly upregulated inhibitory ILT in our study,
is also upregulated in HIV patients and may impair the antigen
presentation of monocytes [43]. Increased expression of another
inhibitory ILT, LILRB4 or ILT3, also impairs antigen presentation
and T cell recruitment as well as modulates the expression of
proinflammatory cytokines [44]. Together, these transcriptional
Figure 5. Differential expression of a Pol II RNA from an unannotated region of Chromosome 14. Panel A. Expression of 59 capped and
poly(A)+ RNAs as measured by signal intensity on ENCODE tiling arrays are displayed using IGB. The data is displayed as in Figure 2 except that each
tick mark represents the normalized mean signal intensity of probes within a 200 nt window. Panel B. qPCR was performed as described in Methods.
Triplicate samples from seven HCV cirrhotic, seven mild HCV (no fibrosis) and ten control livers were analyzed. HCV cirrhotic 1 and Control 1 refer to
original samples used for the ENCODE tiling array analysis. The mean 6 SEM fold change for all specimens analyzed is shown and the location of the
qPCR primers is indicated by qPCR in Panel A.
doi:10.1371/journal.pone.0014697.g005
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viral infection. It should be noted that a number of interferon-
inducible genes previously reported to be upregulated with HCV
infection were not interrogated in our ENCODE tiling array
analysis (representing 1% of the genome) included STAT1, IRF9,
IFI27, CXCL9, CXCL19 and CXCL11 [41,45,46].
A number of gene expression studies of HCV infected liver
biospecimens, done with annotated gene arrays and qPCR, have
been reported. They include studies that identified potential
molecular makers for HCV-associated liver disease and transcript
profiles predictive of both early stage fibrosis and end stage HCV
induced liver disease (cirrhosis) [14,47]. These studies provided
evidence that during late stages of HCV induced liver disease
many of the changes in gene expression observed between HCV-
infected liver as compared to control liver biospecimens are due to
liver fibrosis and not HCV infection. Gene transcripts found to be
upregulated in both early and late stage disease include many
interferon-stimulated genes like STAT1, IRF9, IFI27 and CXCL10
while transcripts involved in growth factor signaling and tissue
remodeling like CTGF, MMP7 and IL8 are more commonly
upregulated during fibrosis [47,48,49]. In our tiling arrays studies,
1% of the genome was interrogated at a high degree of resolution
that included approximately 400 protein coding genes. Therefore
a direct comparison of gene transcripts interrogated in our dataset
compared to whole annotated gene datasets is limited. Neverthe-
less, our gene expression results are consistent with the activation
of interferon signaling pathways in both mild hepatitis C (without
fibrosis) and HCV cirrhotic biospecimens as observed by the
significant upregulation of both liver IRF1 and TRIM22 mRNA
transcripts. In addition, CTGF, considered a biomarker of fibrosis
and cirrhosis, was only upregulated in HCV cirrhotic biospeci-
mens but not in mild hepatitis C without fibrosis similar to
previous reports. With the goal of improving the selection of
patients for current hepatitis C therapies, liver gene expression
signatures predictive of response to therapy have been identified
[13,45,50]. These gene signatures have included interferon
Figure 6. Differential expression of a Pol II RNA from an unannotated region of Chromosome 9. Panel A. Expression of 59 capped and
poly(A)+ RNAs as measured by signal intensity on ENCODE tiling arrays are displayed using IGB. The data is displayed as in Figure 5. Panel B. qPCR
was performed as described in Methods. Triplicate samples from seven HCV cirrhotic, seven mild HCV (no fibrosis) and ten control livers were
analyzed. HCV cirrhotic 1 and Control 1 refer to original samples used for the ENCODE tiling array analysis. The mean 6 SEM fold change for all
specimens analyzed is shown and the location of the qPCR primers is indicated by qPCR in Panel A.
doi:10.1371/journal.pone.0014697.g006
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differentially expressed between responders and non-responders.
Recently IL28B genotype has been found to be a strong predictor
of response to therapy and spontaneous clearance of HCV
[51,52,53,54,55]. A recent report indicates that low interferon
induced gene expression in liver biopsies is a stronger predictor of
treatment response than IL28B genotype in patients with hepatitis
C [56]. The approach we describe may be useful in developing
future panels of gene expression biomarkers for patients with
chronic hepatitis C or other liver disorders that predict clinical
outcomes such as the risk for hepatocellular carcinoma.
We also identified novel unannotated regions showing increased
transcription in both HCV cirrhotic and mild hepatitis C as
compared to control liver including multiple RNA transcripts on
chromosome 14 and an unannotated RNA transcript on chromo-
some 9. It is unknown at this time whether these transcripts represent
protein coding RNAs or non-coding regulatory RNAs. The use of a
sequence analysis tool (BESTORF, www.softberry.com) to predict
potential coding fragments in these unannotated sequences, did not
identify any open reading frames greater than 40 amino acids. This
finding suggests that these transcripts may represent non-coding
RNAs. In addition to the presence of open reading frames (ORF),
both expression level and cross-species sequence homology are
important indicators of the protein coding or non-coding nature of
RNA transcripts [57]. Based on the low expression level of the novel
transcript found in the chromosome 14c region, it’s low sequence
homology to other species, and our inability to identify a poly(A)+ tail
in this transcript, it may indeed represent a non-coding RNA.
Although the other two RNA transcripts on chromosome14 (14a and
14b) and one on chromosome9 were expressed at a higher level,their
low cross species homology suggests they are also non-coding RNAs.
These unannotated expressed regions were evaluated for possible
miRNAs using the informatics program MIREVAL [58]. Although
this analysis identified multiple possible miRNA precursor hairpin
structures in the chromosome 14 transcript, none of these regions
encoded known miRNAs in the miRBase database [59]. Our
evidence that these transcriptionally active regions represent novel
Pol II transcripts is supported by transcription at these same
chromosomal coordinates in published ENCODE analysis of
poly(A)+ RNA from human cell lines [18]. These uncharacterized
Pol II transcripts may represent genes that are part of the host
antiviral defense or those required for specific steps in replication or
release of mature virions. We are currently further defining these
RNAs and testing their biological role in an HCV cell culture system.
We conclude that analyzing 59 capped RNAs in eukaryotic cells
and biospecimens aids the definition of the complete Pol II
transcriptome and increases the sensitivity of identifying differentially
expressed Pol II genes in physiological and pathophysiological states.
This approach should also prove useful in identifying subsets of
mRNAs that are regulated post-transcriptionally by changes in pre-
mRNA splicing or 39 polyadenylation states [33,60,61,62]. Analyzing
differentially selected RNAs, such as 59 capped and poly(A)+ RNA,
with next generation RNA sequencing technologies should be very
useful in fully defining the Pol II transcriptome and identifying
previously undefined PolIItranscripts thataredifferentially expressed
in disease states. In addition, such novel transcripts may prove useful
as biomarkers and may provide insight into the role of ncRNAs in the
development and progression of specific diseases.
Methods
RNA isolation
Total RNA was prepared using TRIzol (Invitrogen). A single
sample from one hepatitis C cirrhotic and one control liver
specimen were used for the initial ENCODE tiling array analysis.
A total of seven hepatitis C cirrhotic liver explants, ten control liver
specimens and seven percutaneous biopsies showing mild hepatitis
C with no fibrosis were used for qPCR analysis. RNA species with
59 m
7GpppN caps were purified using a recombinant GST fusion
high-affinity variant of eIF4E (eIF4EK119A) which binds m
7Gpp
with a tenfold higher affinity as compared to wild-type eIF4E
[23,63]. The 59 capped RNAs were purified as previously
described using GST-eIF4EK119A recombinant protein bound to
glutathione-agarose beads in microfuge tubes by batch purification
[20,64]. The efficiency of this purification is 70% as compared to
30% when wild-type eIF-4E is used in such purifications
(manuscript in preparation). The quantity of 59 capped RNA
was measured by NanoDrop analysis and its integrity confirmed
with an Agilent 2100 Bioanalyzer. Total RNA from the same liver
explants was used as a starting material to purify 59 capped and
poly(A)+ RNA. The poly(A)+ RNA was purified with oligo(dT)
beads (OligotexH, Qiagen) as previously described [20]. The
quantity and integrity of poly(A)+ RNA was determined by the
same measures used for 59 capped RNA.
Human liver pathological specimens
Liver explant pathological specimens from patients undergoing
liver transplantation for chronic hepatitis C with cirrhosis (n=7)
and unused donor (control) liver tissue (n=10) were collected with
IRB approval. HCV cirrhotic liver samples were from both female
and male patients as were the donor liver specimens. Percutaneous
liver biopsy specimens from patients with chronic hepatitis C
found to have mild inflammation and no fibrosis (mild HCV;
Metavir grade 1, stage 0) (n=7) were obtained with IRB approval.
All HCV liver samples were flash frozen in liquid nitrogen
generally within 5 to 10 minutes after biopsy or organ removal.
ENCODE tiling arrays
Four experimental replicate samples of 59 capped RNA isolated
from hepatitis C cirrhotic liver and control liver were used to
produce cDNA using a commercially available kit (Just cDNA
Double-Stranded cDNA Synthesis Kit, Stratagene, La Jolla, CA).
Random hexamers were used to prime first strand cDNA synthesis
from both 59 capped and poly(A)+ RNA samples. The cDNA
product was labeled using an Agilent Genomic DNA Labeling Kit
PLUS by incorporating fluorescently labeled nucleotides (Cy3-
dUTP or Cy5-dUTP) using the exo-Klenow fragment. Following
termination of the labeling reaction, fluorescently labeled cDNA
probes were purified by isopropanol precipitation. Precipitated
pellets were dried and then rehydrated in distilled water. The
concentration of purified oligonucleotides was determined using a
NanoDrop ND-1000 spectrophotometer. A fraction of the labeled
DNA (100 ng) was assayed with an Agilent BioAnalyzer to validate
the size distribution of the labeled cDNA probes.
Fluorescently labeled cDNA probes were heat denatured after
being combined with cot-1 DNA, Agilent aCGH blocking agent
and Agilent Hi-RPM hybridization solution. Microarray hybrid-
izations were performed using Agilent SureHyb chambers
incubated at 65uC for 40 hours with a rotational speed of 20
rpm. Following incubation, the microarray slide was washed for 5
minutes in aCGH/ChIP-on-chip Wash Buffer 1 (0.5X SSPE,
0.005% N-lauroylsarcosine; room temperature) and 5 minutes in a
CGH/ChIP-on-chip Wash Buffer 2 (0.1X SSPE, 0.005% N-
lauroylsarcosine; 31uC). Microarray slides (Agilent ID# 014792)
were briefly dipped in a solution of acetonitrile and dried. Two
microarray slides each were used for labeled cDNA generated
from 59 capped and poly(A)+ RNA from two experimental
replicate samples (HCV cirrhotic and control liver). These slides
ENCODE Analysis of 59 Cap RNA
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replicate samples.
Microarray slides were scanned in an Agilent Technologies
G2505B Microarray Scanner at 5 mm resolution for the
simultaneous detection of Cy-3 and Cy-5 signals. Data captured
from the scanned microarray image was saved as a TIFF image file
and loaded into Agilent Feature Extraction Software version
10.1.1.1. The software automatically positions a grid and finds the
centroid positions of each feature on the microarray. This
information was used to perform calculations that include feature
intensities, background measurements and statistical analyses.
Data generated by the software was recorded as tab-delimited text
files which were processed using the TiMAT2 open-source
software package (http://timat2.sourceforge.net) and results were
visualized and our graphics produced using the Integrated Genome
Browser (IGB) [65].
Bioinformatic Analysis
Data quality. The quality of data was assessed by calculating
all pair Pearson correlation coefficients for each set of biological
replicas using the unadjusted raw median intensity from the
Agilent scan files (R‘2 * 100: 59 capped hepatitis C cirrhotic:
98.6%, 85.2%, 85.4%, 89.5%, 89%, 97.7%; 59 capped control:
97.6%, 95.7%, 90.6%, 94%, 85.3%, 90%; poly(A)+ hepatitis C
cirrhotic: 93.7%, 61.3%, 82.9%, 75.1%, 91.4%, 91.1%; poly(A)+
Control: 91.2%, 91.6%, 90.1%, 91.8%, 94.5%, 94.3%). The mean
R‘2*100 correlation was 89%.
Whole Genome Static Maps. Scaled static maps were made
for comparison in IGB for each of the four datasets (59 capped
control, 59 capped hepatitis C cirrhotic, poly(A)+ control, and
poly(A)+ hepatitis C cirrhotic liver) using the TiMAT2 analysis
package. Agilent’s ENCODE probe sequences were remapped to
the NCBI 36.1 human genome build. For each sample, the four
biological replica raw median probe intensities were quantile
normalized and median scaled to 50 [66]. For each probe, an
average was calculated for the replicas, divided by 50, and log2
transformed.
Whole Genome Dynamic Difference Maps. To identify
regions of change between the different RNA samples (59 capped
HCV cirrhotic compared to 59 capped control and poly(A)+ HCV
cirrhotic compared to poly(A)+ control liver), a sliding window
approach was taken to minimize noise using the TiMAT2 package.
The four test (HCV cirrhotic) and four control remapped raw
median probe intensities were quantile-normalized and median
scaled to 50. Probe level summaries were calculated by taking the
log2 ratio between the mean treatment and mean control.
Window level summaries were calculated by identifying 260 bp
windows that contain 2 or more probes. These windows were
scored by first calculating all the relative difference pairs between
the treatment and the control replica probes, and second, by
calculating the pseudo median of these relative difference pairs.
For display purposes, the pseudo median relative difference scores
were converted to log2 (ratios). To estimate window level FDRs, a
null distribution of random label permutation pseudo median
scored windows was created. The FDR estimation associated each
real pseudo median window score was calculated by dividing the
number of null distribution windows that met or exceeded the
score (false positives) by the number of real windows that exceeded
the score (true positives and false positives). For display purposes,
the FDRs were -10Log10(FDR) transformed. This FDR
estimation was used to score both enriched and reduced
windows. Regions enriched (or reduced) in the HCV cirrhotic
compared to control liver were created by joining overlapping and
adjacent windows (max gap 200 bp) with an FDR of $13
(-10Log10(0.05)). The majority of such regions correspond with
known annotation. To identify potentially novel transcribed
regions, the window arrays were first filtered against those that
intersected any known exonic sequence, using a known gene set
created by combining UCSC’s Known Genes and the Ensembl
gene database [67,68].
Gene-Centric Analysis. A near identical approach was used
to identify genes differentially transcribed in the HCV cirrhotic vs.
control datasets. Instead of a sliding window, normalized probe
intensities falling within the exons of each gene model were
compared using the pseudo median and random label statistics.
Those genes with an FDR $13 and a log2 ratio .0.65 were
considered differentially transcribed.
Bayesian Analysis. Differential gene expression for well-
annotated genes was determined by the regularized t-test, which
uses a Bayesian procedure [69]. Briefly, the expression level of
each gene was assumed to be from a normal distribution with m
and s2. Using a conjugate prior, the mean of the posterior (MP)
estimate of m is the sample mean. The MP estimate of s2 is s2 =
v0s2
0z(n{1)s2
v0zn{2
, where n is the sample size, s
2 is the sample
variance, n0 is the degrees of freedom of the prior (a value of 10 is
used in the analysis), s2
0 is the mean of sample variances of genes in
the neighborhood of the gene under consideration. The
neighborhood was the 50 genes with sample means immediately
above and below the sample mean of the gene under
consideration; that is, the neighborhood consists of the 101
genes centered on the gene. After the MP estimates of m and s2 are
obtained, the t-test of unequal variances was used to calculate a P-
value of differential expression.
Real-time PCR (qPCR). Ten control, seven hepatitis C
cirrhotic liver and seven mild HCV (no fibrosis) specimens were
used for further analysis of differential gene expression in hepatitis
C infected liver tissue. cDNA was prepared from these
pathological specimens and assayed for transcript levels of
selected genes to determine if the same changes in gene
expression observed in the ENCODE array analysis of one
control and disease sample were observed in multiple patients with
hepatitis C as compared to controls. Total RNA from control,
hepatitis C cirrhotic and mild HCV liver was extracted using
TRIzol followed by an RNA cleanup procedure using a RNeasy
Mini kit (Qiagen, Valencia, CA). RNA was treated with DNase I
(Invitrogen, Carlsbad, CA) to remove genomic DNA. First-strand
cDNA was synthesized using Moloney Murine Leukemia Virus
reverse transcriptase (SuperScript III; Invitrogen) with 20 ng/mlo f
RNA at 55uC (60 min) with random hexamers or oligo(dT)
primers. Each PCR reaction was carried out in a 96-well optical
plate (Roche Applied Science) in a 20 ml reaction buffer containing
LightCycler 480 Probes Master Mix (100 mM Tris-HCl, 100 mM
KCl, 400 mM of each dNTP (with dUTP instead of dTTP),
64 mM MgCl2, FastStart Taq DNA Polymerase, 0.3 mM of each
primer, 0.1 mM hydrolysis probe and approximately 50 ng of
cDNA (done in triplicate). Triplicate incubations without template
were used as negative controls. Thermal cycling was done in a
Roche LightCycler 480 System (Roche Applied Science). The
qPCR thermo cycling was 95uC for 5 min, 45 cycles at 95uC for
10 sec, 59uC for 30 sec and 72uC for 1 sec. The relative quantity
of each RNA transcript was calculated with the comparative Ct
(cycling threshold) method using the formula 2
DCt. DCt represents
the difference between target gene expression in control samples
and target gene expression in HCV samples. A reference gene (b-
actin, ACTB) was used as the control and statistical significance
was evaluated using the Student’s T-test.
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the differentially expressed unannotated regions on chromosomes
9 and 14, 59 and 39 rapid amplification of cDNA ends (RACE)
were performed using cDNA made from total RNA and oligo (dT)
primer or 59 capped RNA and random primers. We designed gene
specific primers on the minus and plus strand of one region on
chromosome 9 and three different regions on chromosome 14
(Chr14a, Chr14b, and Chr14c) that were found to be differentially
expressed in HCV cirrhotic liver by ENCODE tiling array
analysis. To verify the chromosome location of each RACE PCR
product, each PCR product was gel purified and cloned using a
TA cloning vector. Cloned products were then sequenced with an
Applied Biosystems 3130xl Genetic Analyzer.
Supporting Information
Figure S1 Differential expression of CTGF in hepatitis C (HCV)
cirrhotic as compared to control liver. Panel A. Expression of
Connective tissue growth factor (CTGF) as measured by signal
intensity on ENCODE tiling arrays is displayed using IGB. The
data are displayed as in Figure 2. Panel B. Real-time PCR (qPCR)
was performed as described in Methods. Triplicate samples from
seven HCV cirrhotic, seven mild HCV (no fibrosis) and ten control
livers were analyzed. HCV cirrhotic 1 and Control 1 refer to
original samples used for the ENCODE tiling array analysis. The
mean + SEM fold change for all specimens analyzed is shown.
Found at: doi:10.1371/journal.pone.0014697.s001 (0.44 MB TIF)
Figure S2 Differential expression of MET in hepatitis C (HCV)
cirrhotic as compared to control liver. Panel A. MET (mesenchy-
mal-epithelial transition factor) is a proto-oncogene that encodes
the tyrosine kinase MET and is also known as c-Met or hepatocyte
growth factor receptor (HGFR). Expression of MET as measured
by signal intensity on ENCODE tiling arrays is displayed using
IGB. The data are displayed as in Figure 2. FDRs are depicted as
negative because this gene showed less expression in hepatitis C
cirrhotic as compared to control liver. Panel B. qPCR was
performed as described in Methods. Triplicate samples from seven
HCV cirrhotic, six mild HCV (no fibrosis), and ten control livers
were analyzed. HCV cirrhotic 1 and Control 1 refer to original
samples used for the ENCODE tiling array analysis. The mean +
SEM fold change for all specimens analyzed is shown. Note that
due to limited quantities of cDNA from mild HCV percutaneous
liver biopsy specimens, duplicates were performed for four
biospecimens and triplicates for two (note SEM bars for assays
done in triplicate).
Found at: doi:10.1371/journal.pone.0014697.s002 (0.53 MB
DOC)
Figure S3 Increased intronic RNA expression from 59 capped
RNA compared to poly(A)+ RNA in HCV cirrhotic and normal
human liver. Panel A, Tissue inhibitor of metalloproteinase 3
(TIMP3); Panel B, Mitogen-activated protein kinase kinase kinase
1 (MAP3K1); and Panel C, MyoD family inhibitor domain
containing (MDFIC) gene transcripts. Expression of 59 capped and
poly(A)+ RNAs as measured by signal intensity on ENCODE
tiling arrays are displayed using IGB.
Found at: doi:10.1371/journal.pone.0014697.s003 (1.36 MB TIF)
Figure S4 Differential expression of a Pol II RNA transcript(s)
originating from an unannotated region of Chromosome 21 in
HCV cirrhotic as compared to control liver. Panel A. Expression
of the unannotated region identified by signal intensity on
ENCODE tiling arrays is displayed using IGB. The data are
displayed as in Figure 5. Panel B. Liver specimens from seven
HCV cirrhotic and seven control livers were analyzed by qPCR in
triplicate. HCV cirrhotic 1 and Control 1 refer to original samples
used for the ENCODE tiling array analysis. The mean + SEM fold
change for all specimens analyzed are shown for the qPCR1
primer set. Results for the second primer set (qPCR2) also did not
show a significant difference between HCV cirrhotic and control
specimens (not shown).
Found at: doi:10.1371/journal.pone.0014697.s004 (1.49 MB TIF)
Figure S5 Differentially expressed unannotated genomic regions
in HCV cirrhotic liver compared with ENCODE data from
human cell lines. The data from high density tiling array analysis
of GM06690 cells (nontumorigenic B lymphocytes), HeLa cells,
and HL60 (human promyelocytic leukemia, predominantly
neutrophilic promyelocyte precursors) cells was loaded into IGB
and aligned with the ENCODE tiling array data that we obtained
in this study. The signal intensity on the ENCODE tiling arrays
are displayed in IGB as in Figure 5. The aligned data provide
evidence that the changes in RNA signals observed in HCV
cirrhotic liver as compared to control liver in the unannotated
region of chromosome 14, 9, and 21 were also observed in the
ENCODE array analysis of GM06690, HL60, and HeLa cells
(http://genome.ucsc.edu/ENCODE/pilot.html). The strongest
signals were observed in the GM06690 cells suggesting that at
least some of the signal in this region observed in HCV cirrhotic
liver was due to lymphoid cells that home to and infiltrate the liver
during chronic hepatitis C.
Found at: doi:10.1371/journal.pone.0014697.s005 (2.11 MB TIF)
Figure S6 Structural characterization of differentially expressed
unannotated Pol II transcripts on chromosome 9 and 14.
Schematic drawing showing an unannotated RNA transcript on
chromosome 9 and 14 identified by Agilent ENCODE tiling array
analysis of 59 capped (green bars) and polyA+ (blue bars) RNA.
Panel A. Chromosome 9 The solid green block represents
sequenced 59 RACE product, with the 59 capped end shown in
black. The arrow at the top of the figure depicts location of qPCR
assay. Human ESTs are depicted in solid black blocks in the
format of the UCSC Genome Browser. The 59 end of multiple
ESTs on the plus strand line up with the 59 end of our 59 RACE
product supporting the existence of a novel RNA transcript in this
region. Repeating elements, also shown in black, depict highly
repetitive nucleotide sequences not tiled on the ENCODE array.
Affymetrix ENCODE tiling array data from a lymphoblastoid cell
line (GM06990, ENCODE pilot project) is presented at the
bottom of the figure (purple bars). Panel B. Chromosome 14 Three
differentially expressed regions upregulated in HCV cirrhotic liver
(14a, 14b, and 14c) are shown in the format of the Integrated
Genome Browser (IGB). Solid green blocks show regions of
sequenced 39 RACE and PCR products, with the poly(A)+ ends
shown in red. Two distinct transcripts on the minus strand of 14a
and 14b regions, respectively, were confirmed by DNA sequenc-
ing. One transcript 1.5 kb in length was confirmed by DNA
sequencing in the 14c region. Two black lines at the top of the
figure depict location of qPCR assays. Human ESTs are depicted
in solid black blocks in the format of the UCSC Genome Browser.
Affymetrix ENCODE tiling array data from a lymphoblastoid cell
line (GM06990, ENCODE pilot project) is presented at the
bottom of the figure (purple bars).
Found at: doi:10.1371/journal.pone.0014697.s006 (0.97 MB TIF)
Table S1 Upregulated genes in HCV cirrhotic liver, identified
only by analyzing 59 capped RNA. RNA transcripts were isolated
from hepatitis C infected and control liver as described in
Methods. cDNA was prepared using random hexamers and
probes prepared as described in Methods. RNA transcript
expression was measured by averaging fluorescent signal intensity
ENCODE Analysis of 59 Cap RNA
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genes with .1.5 fold differences and Bonferoni corrected p-values
,0.05 between hepatitis C infected and control liver are listed.
Differentially expressed genes are categorized by function. Mean
signal intensity, fold change, and p-values for each gene as
determined by analyzing poly(A)+ RNA is included for compar-
ison. Genes that have been previously documented to have
increased expression in HCV infected liver are highlighted marked
with*.
Found at: doi:10.1371/journal.pone.0014697.s007 (0.04 MB
DOCX)
Table S2 Upregulated genes in HCV cirrhotic liver identified
only by analyzing poly(A)+ RNA. Annotated genes tiled on
ENCODE arrays with .1.5 fold change and Bonferoni corrected
p-values ,0.05 are listed by function. Genes that have been
previously documented to have increased expression in HCV
infected liver, hepatocellular carcinoma, or cirrhosis due to other
causes are marked with *.
Found at: doi:10.1371/journal.pone.0014697.s008 (0.04 MB
DOCX)
Table S3 Upregulated genes in HCV cirrhotic liver identified by
analyzing both 59 capped and poly(A)+ RNA. Annotated genes
with a .1.5 fold change and Bonferoni corrected p-value ,0.05
are listed by function. Genes that have been previously reported to
be increased in HCV infected liver, hepatocellular carcinoma or
cirrhosis due to other causes are marked with*.
Found at: doi:10.1371/journal.pone.0014697.s009 (0.04 MB
DOCX)
Table S4 Downregulated genes in HCV cirrhotic liver identified
only by analyzing 59 capped RNA. Annotated genes with a .1.5
fold change and Bonferoni corrected p-values ,0.05 are listed by
function. Genes that have been previously reported to be changed
in hepatitis C infected liver, hepatocellular carcinoma, or cirrhosis
are marked with *.
Found at: doi:10.1371/journal.pone.0014697.s010 (0.04 MB
DOCX)
Table S5 Downregulated genes in HCV cirrhotic liver identified
only by analyzing poly(A)+ RNA. Annotated genes with a .1.5
fold change and Bonferoni corrected p-values ,0.05 are listed by
function.
Found at: doi:10.1371/journal.pone.0014697.s011 (0.03 MB
DOCX)
Table S6 Downregulated genes in HCV cirrhotic liver identified
by analyzing both 59 cap and poly(A)+ RNA. Annotated genes
with a .1.5 fold change and Bonferoni corrected p-values ,0.05
are listed by function.
Found at: doi:10.1371/journal.pone.0014697.s012 (0.03 MB
DOCX)
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